Tuesday, 22 Sep 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Finance
  • Clinical trial results
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline
CompanyDeals

Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline

April 7, 2025
Santen's Tapcom Approved by China's NMPA for Glaucoma Treatment
CompanyDrug

Santen’s Tapcom Approved by China’s NMPA for Glaucoma Treatment

April 7, 2025
Peijia Medical's ReachTactile Robot Assists First Human TAVR Trial
CompanyMedical Device

Peijia Medical’s ReachTactile Robot Assists First Human TAVR Trial

April 7, 2025
Enhertu Approved by EC for Earlier-Line Treatment of HR+/HER2-low Breast Cancer
CompanyDrug

Enhertu Approved by EC for Earlier-Line Treatment of HR+/HER2-low Breast Cancer

April 7, 2025
Sino Biopharmaceutical's TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies
CompanyDrug

Sino Biopharmaceutical’s TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies

April 7, 2025
Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors

April 7, 2025
Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases
CompanyDrug

Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases

April 7, 2025
Sunshine Guojian's SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial
CompanyDrug

Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial

April 7, 2025
Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt
CompanyDrug

Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt

April 7, 2025
Bayer's Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor
CompanyDrug

Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor

April 7, 2025
ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform
CompanyDeals

ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform

April 7, 2025
BeiGene Halts Ociperlimab Clinical Program for Lung Cancer
Company

BeiGene Halts Ociperlimab Clinical Program for Lung Cancer

April 7, 2025
1 2 … 23 24 25 26 27 … 29 30
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up